Abstract
A2B adenosine receptors (A2BARs) are in the focus of interest as drug targets in (immuno)oncology since antagonists show anti-proliferative, anti-angiogenic, anti-metastatic, and immunostimulatory properties. Additional (potential) indications for A2BAR antagonists include inflammatory (pulmonary, colon) and autoimmune diseases, pain, fibrosis, infectious diseases, diabetes, and more. Agonists were found to exhibit cardioprotective properties. The A2BAR is most closely related to the A2AAR subtype. Both are Gs protein-coupled receptors, but the A2BAR is additionally coupled to Gq proteins. A2BAR expression is upregulated under pathological conditions (hypoxia, inflammation, ischemia) and on many cancer cells. A2BARs form stable heteromeric complexes with A2AARs when co-expressed, and thereby completely block A2AAR signaling. There is still a lack of potent, selective, and fully efficacious A2BAR agonists, while structurally diverse potent and selective competitive antagonists for A2BARs have become available. The first positive and negative allosteric modulators for A2BARs were recently described. For the labeling of A2BARs, antagonist radioligands have been developed, and recently the first potent and selective fluorescent ligands were reported.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A et al (2004) Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther 308:358–366
Aherne CM, Saeedi B, Collins CB et al (2015) Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitis. Mucosal Immunol 8:1324–1338
Ali H, Cunha-Melo JR, Saul WF et al (1990) Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor J Biol Chem 265:745–753
Allard B, Beavis PA, Darcy PK et al (2016) Immunosuppressive activities of adenosine in cancer. Curr Opinion Pharmacol 29:7–16
Allard D, Turcotte M, Stagg J (2017) Targeting A2 adenosine receptors in cancer. Immunol Cell Biol 95:333–339
Alnouri MW, Jepards S, Casari A et al (2015) Selectivity is species-dependent: characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. Purinergic Signal 11:389–407
Antonioli L, Pellegrini C, Fornai M et al (2017) Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. Purinergic Signal 13:497–510
Arin RM, Vallejo AI, Rueda Y et al (2015) The A2B adenosine receptor colocalizes with adenosine deaminase in resting parietal cells from gastric mucosa. Biochemistry (Mosc) 80:120–125
Asano T, Takenaga M (2017) Adenosine A2B receptors: an optional target for the Management of Irritable Bowel Syndrome with Diarrhea? J Clin Med 6:E104
Baltos JA, Vecchio EA, Harris MA et al (2017) Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism. Biochem Pharmacol 135:79–89
Baraldi PG, Tabrizi MA, Preti D et al (2004a) Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem 47:1434–1447
Baraldi PG, Tabrizi MA, Preti D et al (2004b) [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. Bioorg Med Chem Lett 14:3607–3610
Baraldi PG, Preti D, Tabrizi MA et al (2007) Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]-9H-purin-9-yl]-N-ethyl-beta-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists. J Med Chem 50:374–380
Baraldi PG, Tabrizi MA, Fruttarolo F et al (2009) Recent improvements in the development of A2B adenosine receptor agonists. Purinergic Signal 5:3–19
Baraldi PG, Baraldi S, Saponaro G et al (2012) Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A2B adenosine receptor antagonists. J Med Chem 55:797–811
Basu S, Barawkar DA, Ramdas V et al (2017a) A2B adenosine receptor antagonists: design, synthesis and biological evaluation of novel xanthine derivatives. Eur J Med Chem 127:986–996
Basu S, Barawkar DA, Ramdas V et al (2017b) Design and synthesis of novel xanthine derivatives as potent and selective A2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases. Eur J Med Chem 134:218–229
Bedford ST, Benwell KR, Brooks T et al (2009) Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor. Bioorg Med Chem Lett 19:5945–5949
Bertarelli DC, Diekmann M, Hayallah AM et al (2006) Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies. Purinergic Signal 2:559–571
Betti M, Catarzi D, Varano F et al (2018) The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor. Eur J Med Chem 150:127–139
Beukers MW, van Oppenraaij J, van der Hoorn PP et al (2004a) Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. Mol Pharmacol 65:702–710
Beukers MW, Chang LC, von Frijtag Drabbe Künzel JK et al (2004b) New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 47:3707–3709
Bilkei-Gorzo A, Abo-Salem OM, Hayallah AM et al (2008) Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia. Naunyn Schmiedeberg's Arch Pharmacol 377:65–76
Borg N, Alter C, Görldt N et al (2017) CD73 on T cells orchestrates cardiac wound healing after myocardial infarction by purinergic metabolic reprogramming. Circulation 136:297–313
Borrmann T, Hinz S, Bertarelli DC et al (2009) 1-Alkyl-8-(piperazine-1-sulfonyl) phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem 52:3994–4006
Borroto-Escuela DO, Hinz S, Navarro G et al (2018) Understanding the role of adenosine A2AR Heteroreceptor complexes in neurodegeneration and Neuroinflammation. Front Neurosci 12:43
Burbiel JC, Ghattas W, Küppers P et al (2016) 2-amino[1,2,4]triazolo[1,5-c]quinazolines and derived novel heterocycles: syntheses and structure-activity relationships of potent adenosine receptor antagonists. ChemMedChem 11:2272–2286
Cagnina RE, Ramos SI, Marshall MA et al (2009) Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 297:L467–L474
Caporarello N, Olivieri M, Cristaldi M et al (2017) Blood-brain barrier in a haemophilus influenzae type a in vitro infection: role of adenosine receptors A2A and A2B. Mol Neurobiol 55:5321–5336
Carbajales C, Azuaje J, Oliveira A et al (2017) Enantiospecific recognition at the A2B adenosine receptor by alkyl 2-cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates. J Med Chem 60:3372–3382
Carotti A, Stefanachi A, Raviña E et al (2004) 8-Substituted-9-deazaxanthines as adenosine receptor ligands: design, synthesis and structure-affinity relationships at A2B. Eur J Med Chem 39:879–887
Carotti A, Cadavid MI, Centeno NB et al (2006) Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor. J Med Chem 49:282–299
Carpenter B, Lebon G (2017) Human adenosine A2A receptor: molecular mechanism of ligand binding and activation. Front Pharmacol 8:898
Casadó V, Casillas T, Mallol J et al (1992) The adenosine receptors present on the plasma membrane of chromaffin cells are of the A2b subtype. J Neurochem 59:425–431
Chandrasekera PC, McIntosh VJ, Cao FX et al (2010) Differential effects of adenosine A2A and A2B receptors on cardiac contractility. Am J Physiol Heart Circ Physiol 299:H2082–H2089
Charles EJ, Mehaffey JH, Sharma AK et al (2017) Lungs donated after circulatory death and prolonged warm ischemia are transplanted successfully after enhanced ex vivo lung perfusion using adenosine A2B receptor antagonism. J Thorac Cardiovasc Surg 154:1811–1820
Chen M, Liang D, Zuo A et al (2015) An A2B adenosine receptor agonist promotes Th17 autoimmune responses in experimental autoimmune uveitis (EAU) via dendritic cell ctivation. PLoS One 10:e0132348
Cheong SL, Venkatesan G, Paira P et al (2011) Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships. Int J Med Chem 2011:480652
Cheung AW, Brinkman J, Firooznia F et al (2010) 4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists. Bioorg Med Chem Lett 20:4140–4146
Choukèr A, Ohta A, Martignoni A et al (2012) In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor. Transplantation 94:894–902
Chugh A, Mookhtiar KA (2017) Design and synthesis of novel xanthine derivatives as potent and selective A2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases. Eur J Med Chem 134:218–229
Cinalli AR, Guarracino JF, Fernandez V et al (2013) Inosine induces presynaptic inhibition of acetylcholine release by activation of A3 adenosine receptors at the mouse neuromuscular junction. Br J Pharmacol 169:1810–1823
Corset V, Nguyen-Ba-Charvet KT, Forcet C et al (2000) Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature 407:747–750
Crespo A, El Maatougui A, Biagini P et al (2013) Discovery of 3,4-dihydropyrimidin-2(1H)-ones as a novel class of potent and selective A2B adenosine receptor antagonists. ACS Med Chem Lett 4:1031–1036
Daly JW, Butts-Lamb P, Padgett W (1983) Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol 3:69–80
Daly JW, Hide I, Müller CE et al (1991) Caffeine analogs: structure-activity relationships at adenosine receptors. Pharmacology 42:309–321
De Filippo E, Namasivayam V, Zappe L, El-Tayeb A, Schiedel AC, Müller CE (2016) Role of extracellular cysteine residues in the adenosine A2A receptor. Purinergic Signal 12:313–329
Doré AS, Robertson N, Errey JC et al (2011) Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19:1283–1293
Doyle C, Cristofaro V, Sack BS et al (2017) Inosine attenuates spontaneous activity in the rat neurogenic bladder through an A2B pathway. Sci Rep 7:44416
Du X, Ou X, Song T et al (2015) Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells. Exp Biol Med 240:1472–1429
Eastwood P, Esteve C, González J et al (2010a) Discovery of LAS101057: a potent, selective, and orally efficacious A2B adenosine receptor antagonist. ACS Med Chem Lett 2:213–218
Eastwood P, Gonzalez J, Paredes S et al (2010b) Discovery of potent and selective bicyclic A2B adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett 20:1634–1637
Eastwood P, Gonzalez J, Paredes S et al (2010c) Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A2B adenosine receptor antagonists. Bioorg Med Chem Lett 20:1697–1700
Eckle T, Kewley EM, Brodsky KS et al (2014) Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. J Immunol 192:1249–1256
El Maatougui A, Azuaje J, González-Gómez M et al (2016) Discovery of potent and highly selective A2B adenosine receptor antagonist chemotypes. J Med Chem 59:1967–1983
Elmenhorst D, Meyer PT, Winz OH et al (2007) Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci 27:2410–2415
Elmenhorst D, Elmenhorst EM, Hennecke E et al (2017) Recovery sleep after extended wakefulness restores elevated A1 adenosine receptor availability in the human brain. Proc Natl Acad Sci U S A 114:4243–4248
El-Tayeb A, Michael S, Abdelrahman A, Behrenswerth A, Gollos S, Nieber K, Müller CE (2011) Development of polar adenosine A2A receptor agonists for inflammatory bowel disease: synergism with A2B antagonists. ACS Med Chem Lett 2:890–895
Elzein E, Kalla RV, Li X et al (2008) Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. J Med Chem 51:2267–2278
Field JJ, Nathan DG, Linden J (2014) The role of adenosine signaling in sickle cell therapeutics. Hematol Oncol Clin North Am 28:287–299
Figueiredo AB, Souza-Testasicca MC, Mineo TWP et al (2017) Leishmania amazonensis-induced cAMP triggered by adenosine A2B receptor is important to inhibit dendritic cell activation and evade immune response in infected mice. Front Immunol 8:849
Firooznia F, Cheung AW, Brinkman J et al (2011) Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity. Bioorg Med Chem Lett 21:1933–1936
Flaten V, Laurent C, Coelho JE et al (2014) From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? Biochem Soc Trans 42:587–592
Floris M, Sabbadin D, Ciancetta A et al (2013) Implementing the “best template searching” tool into Adenosiland platform. In Silico Pharmacol 1:25–32
Franco R, Martínez-Pinilla E, Lanciego JL, Navarro G (2016) Basic pharmacological and structural evidence for class A G-protein-coupled receptor Heteromerization. Front Pharmacol 7:76–81
Fredholm BB, AP IJ, Jacobson KA et al (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527–552
Fredholm BB, AP IJ, Jacobson KA et al (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev 63:1–34
Fuxe K, Agnati LF, Jacobsen K et al (2003) Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61(11 Suppl 6):S19–S23
Gao ZG, Inoue A, Jacobson KA (2018) On the G protein-coupling selectivity of the native A2B adenosine receptor. Biochem Pharmacol 151:201–213
Gatta F, Del Giudice MR, Borioni A et al (1993) Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists. Eur J Med Chem 28:569–576
Geldenhuys WJ, Van der Schyf CJ (2012) Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov 8:115–129
Gewirth DT (2016) Paralog specific Hsp90 inhibitors – a brief history and a bright future. Curr Top Med Chem 16:2779–2791
Giacomelli C, Daniele S, Romei C et al (2018) The A2B adenosine receptor modulates the epithelial- mesenchymal transition through the balance of cAMP/PKA and MAPK/ERK pathway activation in human epithelial lung cells. Front Pharmacol 9:54
Gnad T, Scheibler S, Kügelgen v et al (2014) Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature 516:395–399
Goddard WA 3rd, Kim SK, Li Y et al (2010) Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. J Struct Biol 170:10–20
Goulding J, May LT, Hill SJ (2018) Characterisation of endogenous A2A and A2B receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor biosensor: evidence for an allosteric mechanism of action for the A2B-selective antagonist PSB 603. Biochem Pharmacol 147:55–66
Gracia E, Farré D, Cortés A et al (2013) The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. FASEB J 27:1048–1061
Greer S, Page CW, Joshi T et al (2013) Concurrent agonism of adenosine A2B and glucocorticoid receptors in human airway epithelial cells cooperatively induces genes with anti-inflammatory potential: a novel approach to treat chronic obstructive pulmonary disease. J Pharmacol Exp 346:473–485
Guidolin D, Agnati LF, Marcoli M et al (2015) G-protein-coupled receptor type a heteromers as an emerging therapeutic target. Expert Opin Ther Targets 19:265–283
Hayallah AM, Sandoval-Ramírez J, Reith U et al (2002) 1,8-Disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J Med Chem 45:1500–1510
Herrera C, Casado V, Ciruela F et al (2001) Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol 59:127–134
Hinz S, Lacher SK, Seibt BF et al (2014) BAY60-6583 acts as a partial agonist at adenosine A2B receptors. J Pharmacol Exp Ther 349(3):427–436
Hinz S, Navarro G, Borroto-Escuela D, Seibt BF, Ammon YC, de Filippo E, Danish A, Lacher SK, Červinková B, Rafehi M, Fuxe K, Schiedel AC, Franco R, Müller CE (2018a) Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors. Oncotarget 9:13593–13611
Hinz S, Alnouri WM, Pleiss U, Müller CE (2018b) Tritium-labeled agonists as tools for studying adenosine A2B receptors. Purinergic Signal, in press, https://doi.org/10.1007/s11302-018-9608-5
Hu X, Adebiyi MG, Luo J et al (2016) Sustained elevated adenosine via ADORA2B promotes chronic pain through neuro-immune interaction. Cell Rep 16:106–119
Hutchison KA, Nevins B, Perini F, Fox IH (1990) Soluble and membrane-associated human low-affinity adenosine binding protein (adenotin): properties and homology with mammalian and avian stress proteins. Biochemistry 29:5138–5144
Iannone R, Miele L, Maiolino P et al (2013) Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 15:1400–1409
Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, IJzerman AP, Stevens RC (2008) The 2.6 Ångstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211–1217
Jafari SM, Joshaghani HR, Panjehpour M et al (2018) A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation. Cell Oncol (Dordr) 41:61–72
Jespers W, Oliveira A, Prieto-Díaz R et al (2017) Structure-based design of potent and selective ligands at the four adenosine receptors. Molecules 22:E1945
Jespers W, Schiedel AC, Heitman LH et al (2018) Structural mapping of adenosine receptor mutations: ligand binding and Signaling mechanisms. Trends Pharmacol Sci 39:75–89
Ji X, Kim YC, Ahern DG et al (2001) [3H]MRS 1754, a selective antagonist radioligand for A2B adenosine receptors. Biochem Pharmacol 61:657–663
Johnston-Cox HA, Ravid K (2011) Adenosine and blood platelets. Purinergic Signal 7:357–365
Johnston-Cox H, Koupenova M, Yang D et al (2012) The A2b adenosine receptor modulates glucose homeostasis and obesity. PLoS One 7:e40584
Kaji W, Tanaka S, Tsukimoto M et al (2014) Adenosine A2B receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells. J Toxicol Sci 39:191–198
Kalhan A, Gharibi B, Vazquez M et al (2012) Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy. Purinergic Signal 8:265–274
Kalla RV, Elzein E, Perry T et al (2008) Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines. Bioorg Med Chem Lett 18:1397–1401
Kalla RV, Zablocki J, Tabrizi MA et al (2009) Recent developments in A2B adenosine receptor ligands. Handb Exp Pharmacol 193:99–122
Karmouty-Quintana H, Zhong H, Acero L et al (2012) The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J 26:2546–2557
Karmouty-Quintana H, Philip K, Acero LF et al (2015) Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J 29:50–60
Kim SA, Marshall MA, Melman N et al (2002) Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 45:2131–2138
Konrad FM, Zwergel C, Ngamsri KC et al (2017) Anti-inflammatory effects of heme oxygenase-1 depend on adenosine A2A- and A2B-receptor signaling in acute pulmonary inflammation. Front Immunol 8:1874
Koscsó B, Csóka B, Selmeczy Z et al (2012) Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J Immunol 188:445–453
Köse M, Schiedel AC (2009) Nucleoside/nucleobase transporters: drug targets of the future? Future Med Chem 1:303–326
Köse M, Gollos S, Karcz T, Fiene A, Heisig F, Behrenswerth A, Kiec-Kononowicz KJ, Namasivayam V, Müller CE (2018) Fluorescent-labeled selective adenosine A receptor antagonist enables competition binding assay by flow cytometry. J Med Chem 61(10):4301–4316
Koupenova M, Johnston-Cox H, Vezeridis A et al (2012) A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation 125:354–363
Lazarus M, Chen JF, Huang ZL et al (2017) Adenosine and sleep. Handb Exp Pharmacol. https://doi.org/10.1007/164_2017_36
Lebon G, Warne T, Edwards PC et al (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521–525
Lebon G, Edwards PC, Leslie AG et al (2015) Molecular determinants of CGS21680 binding to the human adenosine A2A receptor. Mol Pharmacol 87:907–915
Li Q, Han X, Lan X et al (2017) Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia. Neurobiol Dis 108:173–182
Linden J, Thai T, Figler H et al (1999) Characterization of human A2B adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol 56:705–713
Liu W, Chun E, Thompson AA et al (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232–236
Liu R, Groenewoud NJ, Peeters MC et al (2014) A yeast screening method to decipher the interaction between the adenosine A2B receptor and the C-terminus of different G protein α-subunits. Purinergic Signal 10:441–453
Liu R, Nahon D, le Roy B et al (2015) Scanning mutagenesis in a yeast system delineates the role of the NPxxY(x)(5,6)F motif and helix 8 of the adenosine A2B receptor in G protein coupling. Biochem Pharmacol 95:290–300
Ma DF, Kondo T, Nakazawa T, Niu DF, Mochizuki K, Kawasaki T, Yamane T, Katoh R (2010) Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol 41:1550–1557
Matharu AL, Mundell SJ, Benovic JL et al (2001) Rapid agonist-induced desensitization and internalization of the a(2B) adenosine receptor is mediated by a serine residue close to the COOH terminus. J Biol Chem 276:30199–30207
McGuinness BF, Ho KK, Stauffer TM et al (2010) Discovery of novel quinolinone adenosine A2B antagonists. Bioorg Med Chem Lett 20:7414–7420
Methner C, Schmidt K, Cohen MV et al (2010) Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 299:H1262–H1264
Michael S, Warstat C, Michel F et al (2010) Adenosine A2A agonist and A2B antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation. Purinergic Signal 6:117–124
Mittal D, Sinha D, Barkauskas D et al (2016) Adenosine 2B receptor expression on Cancer cells promotes metastasis. Cancer Res 76:4372–4382
Moidunny S, Vinet J, Wesseling E et al (2012) Adenosine A2B receptor-mediated leukemia inhibitory factor release from astrocytes protects cortical neurons against excitotoxicity. J Neuroinflammation 9:198–204
Molck C, Ryall J, Failla LM et al (2016) The A2b adenosine receptor antagonist PSB-603 promotes oxidative phosphorylation and ROS production in colorectal cancer cells via adenosine receptor-independent mechanism. Cancer Lett 383:135–143
Morello S, Pinto A, Blandizzi C et al (2016) Myeloid cells in the tumor microenvironment: role of adenosine. Oncoimmunology 5:e1108515
Moro S, Hoffmann C, Jacobson KA (1999) Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry 38:3498–3507
Müller CE, Jacobson KA (2011a) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta1808:1290–1308
Müller CE, Jacobson KA (2011b) Xanthines as adenosine receptor antagonists. Handb Exp Pharmacol 200:151–199
Müller CE, Scior T (1993) Adenosine receptor and their modulators. Pharm Acta Helv 68:77–111
Müller CE, Stein B (1996) Adenosine receptor antagonists: structures and potential therapeutic applications. Curr Pharm Des 2:501–530
Mundell SJ, Matharu AL, Nisar S et al (2010) Deletion of the distal COOH-terminus of the A2B adenosine receptor switches internalization to an arrestin- and clathrin-independent pathway and inhibits recycling. Br J Pharmacol 159:518–533
Nascimento FP, Macedo-Júnior SJ, Pamplona FA et al (2015) Adenosine A1 receptor-dependent antinociception induced by inosine in mice: pharmacological, genetic and biochemical aspects. Mol Neurobiol 51:1368–1378
Nieto MI, Balo MC, Brea J et al (2010) Synthesis and pharmacological evaluation of novel substituted 9-deazaxanthines as A2B receptor antagonists. Eur J Med Chem 45:2884–2892
Orozco-Gregorio H, Mota-Rojas D, Villanueva D et al (2011) Caffeine therapy for apnoea of prematurity: pharmacological treatment. African J Pharm Pharmacol 5:564–571
Ortore G, Martinelli A (2010) A2B receptor ligands: past, present and future trends. Curr Top Med Chem 10:923–940
Panjehpour M, Castro M, Klotz KN (2005) Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal. Br J Pharmacol 145:211–218
Patel L, Thaker A (2015) The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy. J Pharmacol Pharmacother 6:147–153
Peeters MC, van Westen GJ, Guo D et al (2011) GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J 25:632–643
Peeters MC, Li Q, Elands R et al (2014) Domains for activation and inactivation in G protein-coupled receptors--a mutational analysis of constitutive activity of the adenosine A2B receptor. Biochem Pharmacol 92:348–357
Pejman L, Omrani H, Mirzamohammadi Z et al (2014) The effect of adenosine A2A and A2B antagonists on tracheal responsiveness, serum levels of cytokines and lung inflammation in Guinea pig model of asthma. Adv Pharm bull 4:131–138
Petroni D, Giacomelli C, Taliani S et al (2016) Toward PET imaging of A2B adenosine receptors: a carbon-11 labeled triazinobenzimidazole tracer: synthesis and imaging of a new A2B PET tracer. Nucl Med Biol 43:309–317
Philip K, Mills TW, Davies J et al (2017) HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis. FASEB J 31:4745–4758
Phosri S, Arieyawong A, Bunrukchai K, Parichatikanond W, Nishimura A, Nishida M, Mangmool S (2017) Stimulation of adenosine A2B receptor inhibits endothelin-1-induced cardiac fibroblast proliferation and α-Smooth muscle actin synthesis through the cAMP/Epac/PI3K/Akt-signaling pathway. Front Pharmacol 8:428
Pierce KD, Furlong TJ, Selbie LA et al (1992) Molecular cloning and expression of an adenosine A2b receptor from human brain. Biochem Biophys Res Commun 187:86–93
Pleli T, Mondorf A, Ferreiros N et al (2018) Activation of adenylyl cyclase causes stimulation of adenosine receptors. Cell Physiol Biochem 45:2516–2528
Raghavendra NM, Pingili D, Kadasi S et al (2018) Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem 143:1277–1300
Rüsing D, Müller CE, Verspohl EJ (2006) The impact of adenosine and A2B receptors on glucose homoeostasis. J Pharm Pharmacol 58:1639–1645
Ryzhov S, Biktasova A, Goldstein AE et al (2014) Role of JunB in adenosine A2B receptor-mediated vascular endothelial growth factor production. Mol Pharmacol 85:62–73
Sassi Y, Ahles A, Truong DJ et al (2014) Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. J Clin Invest 124:5385–5397
Schiedel AC, Hinz S, Thimm D et al (2011) The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: role in ligand binding and receptor function. Biochem Pharmacol 82:389–399
Schiedel AC, Lacher SK, Linnemann C et al (2013) Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms. Purinergic Signal 9:351–365
Seibt BF, Schiedel AC, Thimm D et al (2013) The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A2 adenosine receptors. Biochem Pharmacol 85:1317–1329
Sepulveda C, Palomo I, Fuentes E (2016) Role of adenosine A2b receptor overexpression in tumor progression. Life Sci 166:92–99
Sherbiny FF, Schiedel AC, Maass A et al (2009) Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the β2-adrenergic receptor and the human adenosine A2A receptor. J Comput Aided Mol Des 23:807–828
Sorrentino C, Miele L, Porta A et al (2015) Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget 6:27478–27489
Stefanachi A, Brea JM, Cadavid MI et al (2008) 1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor. Bioorg Med Chem 16:2852–2869
Stehle JH, Rivkees SA, Lee JJ et al (1992) Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol Endocrinol 6:384–393
Stewart M, Steinig AG, Ma C et al (2004) [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem Pharmacol 68:305–312
Sun Y, Huang P (2016) Adenosine A2B receptor: from cell biology to human diseases. Front Chem 4:37–43
Sun Y, Hu W, Yu X et al (2016) Actinin-1 binds to the C-terminus of A2B adenosine receptor (A2BAR) and enhances A2BAR cell-surface expression. Biochem J 473:2179–2186
Taliani S, Pugliesi I, Barresi E et al (2012) 3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A2B adenosine receptor antagonists. J Med Chem 55:1490–1499
Taliani S, Trincavelli ML, Cosimelli B et al (2013) Modulation of A2B adenosine receptor by 1-benzyl-3-ketoindole derivatives. Eur J Med Chem 69:331–337
Thimm D, Schiedel AC, Sherbiny FF et al (2013) Ligand-specific binding and activation of the human adenosine A2B receptor. Biochemistry 52:726–740
Toldo S, Zhong H, Mezzaroma E et al (2012) GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther 343:587–595
Trincavelli ML, Giacomelli C, Daniele S et al (2014) Allosteric modulators of human A2B adenosine receptor. Biochim Biophys Acta 1840:1194–1203
Vecchio EA, Tan CY, Gregory KJ et al (2016a) Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation. J Pharmacol Exp Ther 357:36–44
Vecchio EA, Chuo CH, Baltos JA et al (2016b) The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. Biochem Pharmacol 117:46–56
Wei Q, Costanzi S, Balasubramanian R et al (2013a) A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal 9:271–280
Wei W, Du C, Lv J et al (2013b) Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J Immunol 190:138–146
Welihinda AA, Kaur M, Raveendran KS et al (2018) Enhancement of inosine-mediated A2AR signaling through positive allosteric modulatiion. Cell Signal 42:227–235
Weller J, Pose M, Protzel C et al (2015) Age-related decrease of adenosine-mediated relaxation in rat detrusor is a result of A2B receptor downregulation. Int J Urol 22:322–329
Wen J, Wang B, Du C et al (2015) A2B adenosine receptor agonist improves erectile function in diabetic rats. Tohoku J Exp Med 237:141–148
Xu F, Wu H, Katritch V et al (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322–327
Yan L, Müller CE (2004) Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. J Med Chem 47:1031–1043
Yan L, Bertarelli DC, Hayallah AM et al (2006) A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists. J Med Chem 49:4384–4391
Yang Y, Qiu Y, Wang W et al (2014) Adenosine A2B receptor modulates intestinal barrier function under hypoxic and ischemia/reperfusion conditions. Int J Clin Exp Pathol 7:2006–2018
Zablocki J, Kalla R, Perry T et al (2005) The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma. Bioorg Med Chem Lett 5:609–612
Zhang H, Zhong H, Everett TH 4th et al (2014) Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. Heart Rhythm 11:101–109
Zhou QY, Li C, Olah ME et al (1992) Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A 89:7432–7436
Zhou Y, Chu X, Deng F et al (2017) The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway. Oncotarget 8:48755–48768
Zimmermann H, Zebisch M, Sträter N (2012) Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8:437–502
Acknowledgments
We are grateful to the Federal Ministry of Education and Research (BMBF), Germany, for the support of a project on the development of A2BAR antagonists as diagnostics for PET imaging within the BioPharma initiative (Neuroallianz, project D11B). We thank A.C. Schiedel for the design of Fig. 6.4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Müller, C.E., Baqi, Y., Hinz, S., Namasivayam, V. (2018). Medicinal Chemistry of A2B Adenosine Receptors. In: Borea, P., Varani, K., Gessi, S., Merighi, S., Vincenzi, F. (eds) The Adenosine Receptors. The Receptors, vol 34. Humana Press, Cham. https://doi.org/10.1007/978-3-319-90808-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-90808-3_6
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-90807-6
Online ISBN: 978-3-319-90808-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)